Research Reference
Octreotide
FDA-approved somatostatin analog for acromegaly and NETs
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Octreotide (Sandostatin) is an FDA-approved somatostatin analog used for acromegaly and neuroendocrine tumors.
Dosing Reference
Reconstitution
Add 5 mL bacteriostatic water to the 0.5 mg vial. Resulting concentration: 0.1 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 100 mcg | 100 units | 1 mL | SubQ, 3x dailyImmediate-release (FDA) |
| 200 mcg | 200 units | 2 mL | SubQ, 3x dailyHigher IR dose (FDA) |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Octreotide (Sandostatin, Sandostatin LAR) is FDA-approved for acromegaly, carcinoid syndrome, VIP-secreting tumors, and esophageal variceal bleeding. It is supplied as an immediate-release subcutaneous injection (50/100/500 mcg/mL vials) or a long-acting intramuscular depot (LAR, 10/20/30 mg). The LAR depot is reconstituted per the kit instructions only. Compounded research-peptide forms are not FDA-approved.
For a compounded 0.5 mg vial reconstituted with 5 mL, the concentration is 0.1 mg/mL; a 100 mcg dose draws to 10 units (1 mL) on a U-100 syringe. Store per manufacturer directions; compounded forms are not FDA-approved.
Cycling Protocol
FDA-approved octreotide IR is dosed 100–600 mcg subcutaneously 3 times daily, titrated to response. The LAR depot is 20–30 mg intramuscularly every 4 weeks. Used as chronic therapy; no fixed cycle end.
Routes of Administration
Subcutaneous injection (IR, FDA-approved): 3 times daily into the abdomen or thigh for acromegaly/carcinoid.
Compounded forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Acromegaly | Octreotide + pegvisomant / dopamine agonist | Combination protocols (FDA, under endocrinology supervision) |
Octreotide combinations are managed under specialist endocrinology/oncology supervision. Compounded forms are not FDA-approved.
Side Effects & Safety
- GI effects — nausea, diarrhea, abdominal cramps, steatorrhea (common)
- Gallbladder abnormalities / gallstones — common with long-term use
- Hyperglycemia / hypoglycemia — glucose dysregulation
- Injection-site pain — common
- Bradycardia — possible
- Pancreatitis — rare
- B12 / fat-soluble vitamin malabsorption — risk with long-term use
Octreotide (Sandostatin/Sandostatin LAR) is FDA-approved for acromegaly, carcinoid syndrome, VIP tumors, and variceal bleeding. Compounded research-peptide forms are not FDA-approved.
Research Basis
Octreotide is a synthetic somatostatin analog (octapeptide), FDA-approved (Sandostatin).
Mechanism: Agonizes somatostatin receptors (SSTR1–5, predominantly SSTR2/SSTR5), inhibiting secretion of growth hormone, insulin, glucagon, gastrin, and various peptide hormones; also reduces splanchnic blood flow.
Clinical evidence: FDA-approved for acromegaly, carcinoid syndrome, VIP-secreting tumors, and esophageal variceal bleeding. Extensive clinical experience.
FDA-approved for the indications above. Compounded research-peptide forms are not FDA-approved.